Ipamorelin + Tesamorelin 10mg Blend (5+5 mg)
A dual-action 1:1 GH secretagogue blend pairing a stabilized GHRH analog with a selective ghrelin receptor agonist for experimental research.
Mechanism
Combines GHRH receptor activation via Tesamorelin with selective GHS-R1a stimulation via Ipamorelin to induce dual-pathway, additive pulsatile growth hormone secretion.
Dosing
Standard experimental protocols document an initial daily dose of 330 mcg total blend administered via subcutaneous injection.
Reconstitution
Reconstituting the 10 mg blend vial with 3.0 mL bacteriostatic water yields an approximate working concentration of 3.33 mg/mL (about 1.67 mg/mL per constituent).
Storage
Store unmixed lyophilized vials at -20 °C protected from moisture, and keep the reconstituted solution refrigerated at 2–8 °C without freezing.
Mix & measure Ipamorelin + Tesamorelin 10mg Blend (5+5 mg)
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Ipamorelin + Tesamorelin 10mg Blend (5+5 mg)
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 30.3
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–4 (Standard) | 330 mcg total (1× daily) | 10 units (0.10 mL) |
| Weeks 5–8 (Standard) | 500 mcg total (1× daily) | 15 units (0.15 mL) |
| Weeks 1–4 (Advanced) | 500 mcg total (1× daily) | 10 units (0.10 mL) |
| Weeks 5–8 (Advanced) | 1000 mcg total (1× daily) | 20 units (0.20 mL) |
Reconstitution Steps
- 1
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
- 2
Introduce the diluent slowly down the interior glass wall of the blend vial to minimize agitation and foaming.
- 3
Gently swirl or roll the vial until the lyophilized cake fully dissolves into a clear solution; avoid shaking.
- 4
Mark the vial with the preparation date and resulting concentration, then store immediately at 2–8 °C away from light.
Supplies Needed
Peptide Vial
Lyophilized Ipamorelin + Tesamorelin 10 mg (5+5 mg) research material
Insulin Syringes (U-100)
Calibrated 1 mL syringes for precise measurement and subcutaneous administration
Bacteriostatic Water
Sterile diluent containing 0.9% benzyl alcohol for dissolving the lyophilized peptides
Alcohol Swabs
Disinfection of the vial rubber stopper and test site surfaces prior to injection
Why researchers study it
Dual-pathway GH and IGF-1 axis stimulation
Mechanisms of visceral adipose tissue reduction
Effects on body composition and lean muscle maintenance
Deep sleep architecture and cellular recovery dynamics
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
This formulation co-administers equal parts Ipamorelin and Tesamorelin within a single 10 mg lyophilized matrix, presenting a fixed 1:1 peptide ratio. Tesamorelin acts as a synthetic growth hormone-releasing factor derivative that engages anterior pituitary receptors, while Ipamorelin serves as a selective pentapeptide targeting growth hormone secretagogue receptors. By combining these complementary biochemical pathways, the blend is designed to stimulate endogenous growth hormone pulses with greater magnitude than either compound could achieve alone at modest concentrations. Investigators primarily evaluate this dual-axis combination to explore its potential downstream impacts on serum IGF-1 elevation, visceral adipose tissue lipolysis, and nocturnal physiological repair. Tesamorelin provides the baseline signaling akin to natural hypothalamic releasing hormones, while Ipamorelin's selective agonism amplifies pituitary release without provoking significant elevations in unwanted regulatory markers like cortisol or prolactin. All documented protocols emphasize that fixed-ratio blends require concurrent titration of both agents, precluding individual adjustment of either constituent. Given the biological potency across the somatotropic axis, researchers monitor metabolic parameters including fasting insulin sensitivity and glucose markers throughout experimental cycles.
References
- 1.Falutz et al., New England Journal of Medicine, 2007 — Effects of tesamorelin on visceral abdominal fat in HIV-associated lipodystrophy
- 2.Falutz et al., Clinical Infectious Diseases, 2010 — Long-term safety and efficacy of tesamorelin on visceral fat and IGF-1
- 3.Raun et al., European Journal of Endocrinology, 1998 — Characterization of ipamorelin as a selective growth hormone secretagogue
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allB7-33 10mg
A synthetic single-chain relaxin-2 mimetic engineered to selectively activate RXFP1 signaling for preclinical anti-fibrotic research.
View ProtocolMelanotan II 10mg
Synthetic melanocortin receptor agonist evaluated in preclinical models for skin pigmentation, libido stimulation, and appetite modulation.
View ProtocolLarazotide 5mg
An oral, gut-restricted octapeptide tight-junction regulator researched for paracellular barrier permeability and celiac disease models.
View Protocol